secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001104659-21-133095
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte reports 3 product complaints for Opzelura cream; suspends affected batches
--------------------------------------------------------------------------------

- Three product complaints received for Opzelura (ruxolitinib) cream related to texture.
- FDA notified; root cause analysis underway; early testing shows no safety/efficacy issues.
- Texture issue due to small amount of API not fully dissolved, causing slight gritty texture.
- Distribution of affected batches suspended; no commercial supply issues at this time.
- 60g tubes that passed release and 90-day QC remain available; manufacturing continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000110465921133095/0001104659-21-133095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000110465921133095/tm2131721d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-133095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer